Regulatory10 April 2026 at 01:41 pm
Torrent Pharma's Bileshwarpura Oncology facility gets Zero USFDA observations
AI Summary
Torrent Pharmaceuticals announced that its Bileshwarpura (Oncology) manufacturing facility underwent an inspection by the US Food and Drug Administration (USFDA) from April 6, 2026, to April 10, 2026. The company reported that the inspection concluded with zero observations, indicating full compliance with USFDA standards. This positive outcome is significant for Torrent Pharma's operations in the US market, particularly for its oncology product portfolio, as it ensures continued regulatory approval and market access. It reflects robust quality control and manufacturing processes at the facility.
Key Highlights
- USFDA inspected Torrent Pharma's Bileshwarpura Oncology facility.
- Inspection occurred from April 6 to April 10, 2026.
- The facility received zero observations from the USFDA.
- This ensures continued regulatory compliance for US market.
- Positive for company's oncology product portfolio.